When evaluating the implementation of the more advanced fluorescent in situ hybridisation (FISH) testing for reflex testing human EGFR 2 (HER2) amplifications in breast cancer, Garrison et al. [45] stated that it was unclear whether payers would finance the more rigorous test over the commonly used immunohistochemistry test (IHC). Here, EGFR is linked to breast cancer.